Molecular markers, such as O6-methylguanine-DNA methyltransferase (MGMT) methylation, codeletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p/19q), mutations in isocitrate dehydrogenase (IDH), mutations in alpha thalassemia/mental retardation syndrome X-linked, and epidermal growth factor receptor are being used in molecular pathological diagnosis, treatment options, and prognostic evaluation with glioma patients (Zeng et al., 2015). This evidence concerns the gene MGMT and Alpha-thalassemia.